Clinical trials: Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis.
- Trial name
- NCT00662649
- Testing
- Fingolimod 0.5 mg, Fingolimod 1.25 mg
- Where
- 103 sites in Australia, Belgium and 20 more
- Volunteers
- 920 people
- Sponsor
- Novartis
Multiple Sclerosis
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
- Trial name
- NCT01395316
- Testing
- Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Relapsing-Remitting Multiple Sclerosis
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012…
- Trial name
- TOLERATE (NCT02125604)
- Testing
- dimethyl fumarate
- Where
- 19 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Biogen
Multiple Sclerosis
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.
- Trial name
- BECOME (NCT00176592)
- Testing
- Betaseron, Copaxone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who…
- Trial name
- LemKids (NCT03368664)
- Testing
- Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon
- Where
- 13 sites in France, Italy and 4 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing-Remitting Multiple Sclerosis
CLARITY Extension Study
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY).
- Trial name
- NCT00641537
- Testing
- Cladribine
- Where
- 116 sites in United States, Australia and 29 more
- Volunteers
- 867 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Remitting Multiple Sclerosis
Vitamin D Supplementation in Multiple Sclerosis
Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks.
- Trial name
- NCT01490502
- Testing
- Vitamin D3
- Where
- 16 sites in United States
- Volunteers
- 172 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02525874
- Testing
- dimethyl fumarate
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 218 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
- Trial name
- NCT00078338
- Testing
- Rebif®, Copaxone®
- Where
- 80 sites in United States, Argentina and 10 more
- Volunteers
- 764 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis (RRMS)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- RED4MS (NCT06430671)
- Testing
- CLS12311 low, CLS12311 medium, CLS12311 high
- Where
- 8 sites in Czechia, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Cellerys AG
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
RNF and Betaseron® Tolerability Study
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes…
- Trial name
- REFORMS (NCT00428584)
- Testing
- New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- EMD Serono
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.